cellvie Inc., the leader in Therapeutic Mitochondria Transfer (TMT) and a Harvard University spin-off, closes a $5M round to advance its product pipeline, including a first application in rejuvenation.
Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinson’s and Alzheimer’s, over heart attacks and strokes, to age-related degeneration.
“But treating mitochondria has proven to be an arduous challenge” said Dr. James McCully, a founder of cellvie and Associate Professor of Surgery at Boston’s Children’s Hospital and Harvard Medical School where he pioneered the therapeutic use of mitochondria. “That is why we turned to introducing healthy, viable mitochondria into cells where these organelles are impaired. To great effect. We can sustainably reinvigorate cells’ failing energy metabolism.”
The potential of Therapeutic Mitochondria Transfer was recently demonstrated in a clinical investigation at Boston Children’s Hospital. Pediatric patients on heart-lung-support after suffering a cardiogenic shock, received the treatment to revitalize their heart muscle. 80% of these children experienced myocardial recovery, which compares to an expected 29%, as reported in a publication forthcoming in The Journal of Thoracic and Cardiovascular Surgery.
“The implications of our findings are groundbreaking. We may have the chance to bring about a new treatment modality,” said Dr. Alexander Schueller, founder and CEO of cellvie. “The investment will enable us to pursue the platform broadly, including a first application in aging, where the need for mitochondria-recovery is particularly dear.”
To date, cellvie focused primarily on ischemia-reperfusion injury (IRI), one of the world’s leading causes of death. IRI manifests itself whenever the blood flow to a part of the body is interrupted and subsequently reintroduced. Well-known medical conditions include heart attacks, strokes, and organ transplantation. cellvie is pursuing an indication in organ transplantation, first, for which the FDA awarded orphan drug designation in 2020. The capital injection will be employed for productization,
to expand cellvie’s product pipeline and to prepare an IND submission for a clinical study in kidney transplantation.
“We were immediately attracted to the potential of cellvie’s approach to emerge as a novel category of medicines” said Frank Schueler, Managing Director at Kizoo Technology Capital. “With mitochondria dysfunction a common denominator to disease and aging alike, cellvie’s ability to affect the cell energy metabolism may pave the road to address hitherto intractable human ailments.” Frank Schueler will join the company’s Board of Directors.